Amylyx Pharmaceuticals is withdrawing its FDA-approved therapy for amyotrophic lateral sclerosis, Relyvrio, from the market after a phase 3 study failure, the company said April 4.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
